Myelodysplastic Syndromes
Clinical and Biological Advances

Myelodysplastic Syndromes: Clinical and Biological Advances stands out as the definitive text on the genetics, pathophysiology, and clinical management of this wide range of syndromes. Written by international experts, this book provides a state-of-the-art update of the current status and recent advances in the field. The chapters cover all aspects of the myelodysplastic syndromes, from an in-depth analysis of the multifactorial nature of this disease, including a careful assessment of stromal, immunological, and stem cell abnormalities, to a review of recent molecular and cytogenetic discoveries and insights. This book will be a valuable resource for clinicians and researchers who wish to learn more about myelodysplastic syndromes.

Peter L. Greenberg is Professor of Medicine at Stanford University Cancer Center, Stanford, and Chief, Hematology Section, VA Palo Alto Health Care System, Palo Alto, California, USA.
Myelodysplastic Syndromes
Clinical and Biological Advances

Edited by
Peter L. Greenberg
Stanford University Cancer Center, Stanford and
VA Palo Alto Health Care System, Palo Alto
To Suzanne, Sarah, Daniel, Miriam, and, of course, Simi, whose love, encouragement, and support have been critical beacons for my worlds; to my MDS colleagues for their spirited camaraderie and scientific stimulation; to my patients with MDS who have permitted me the privilege of participating in their lives and struggles, who have taught me much of the eternal odds they/we face. All have been vital for my ongoing exploration to better comprehend and treat this distinctively problematic disease.
Contents

List of contributors ix
Preface xi

1 Clinical and prognostic characterization of myelodysplastic
syndromes 1
Peter L. Greenberg

2 Morphologic classifications of myelodysplastic syndromes:
French–American–British (FAB) and World Health
Organization (WHO) 33
Richard D. Brunning

3 Pathogenetic mechanisms underlying myelodysplastic syndromes
Peter L. Greenberg 63

4 Cytogenetic abnormalities in myelodysplastic syndromes
Harold J. Olney and Michelle M. Le Beau 95

5 Molecular mechanisms and gene expression patterns in
myelodysplastic syndromes 129
Wolf-Karsten Hofmann and H. Phillip Koef er

6 Immunologic mechanisms and treatment of myelodysplastic
syndromes 147
A. John Barrett, Elaine Sloand and Neal S. Young

7 Biologically targeted therapies for myelodysplastic syndromes
Andrew J. Buresh and Alan F. List 173
Contents

8 Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy 209
Jason Gotlib and Peter L. Greenberg

9 Hematopoietic cell transplantation for myelodysplastic syndromes 243
H. Joachim Deeg and Bart Scott

10 Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement, and implications for research and practice 263
Mary Laudon Thomas

Index 297
Contributors

A. John Barrett MD
Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health
9000 Rockville Pike, Bldg 10, Room 7C103
Bethesda MD 20892
USA

Richard D. Brunning MD
University of Minnesota Hospital
Department of Laboratory Medicine and Pathology
Box 609
Minneapolis MN 55455
USA

Andrew J. Buresh MD
University of Arizona Medical Center
Hematology Unit
1515 N. Campbell Ave
Tucson AZ 85724
USA

H. Joachim Deeg MD
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North, D1-100
P O Box 19024
Seattle WA 98109-1024
USA

Jason Gotlib MD MS
Stanford University Cancer Center
Division of Hematology
875 Blake Wilbur Drive
Room 2335
Stanford CA 94305
USA

Peter L. Greenberg MD
Stanford University Cancer Center
Division of Hematology
875 Blake Wilbur Drive
Stanford CA 94305-5821
USA and Hematology Section
VA Palo Alto Health Care System
Palo Alto CA 94304
USA

Wolf-Karsten Hofmann MD
University Hospital "Benjamin Franklin"
Department of Hematology, Oncology and Transfusion Medicine
Hindenburgdamm 30
12203 Berlin
Germany
x List of contributors

H. Phillip Koeffler MD
UCLA School of Medicine
Division of Hematology/Oncology
Cedars Sinai Research Institute
8700 Beverly Blvd, B-208
Los Angeles CA 90048
USA

Michelle M. Le Beau PhD
University of Chicago
Section of Hematology/Oncology
5841 S. Maryland, MC2115
Chicago IL 60637
USA

Alan F. List MD
University of South Florida
Moffitt Clinic Center, Hematologic Malignancies Program
Department of Interdisciplinary Oncology
12902 Magnolia Drive
Tampa FL 33612-9497
USA

Harold J. Olney MD CM
Université de Montréal
CHUM Hôpital Notre-Dame
1560 Sherbrooke Street East
Montreal
Quebec H2L 4M
Canada

Bart Scott MD
Fred Hutchinson Cancer Research Center
825 Eastlake Ave E, PO Box 19023
Seattle WA 98109-1023
USA

Elaine Slaund MD
Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health
9000 Rockville Pike, Bldg 10, Room 7C103
Bethesda MD 20892
USA

Mary Laudon Thomas RN MS AOCN
Veterans Affairs Palo Alto Health Care System
3801 Miranda Avenue
Palo Alto CA 94304
USA

Neal S. Young MD
Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health
9000 Rockville Pike, Bldg 10, Room 7C103
Bethesda MD 20892
USA
Preface

Myelodysplastic syndrome (MDS) is a particularly problematic disease. This myeloid clonal hemopathy is heterogeneous, with varying stages having differing clinical problems that require specific yet disparate therapeutic approaches. Major morbidity relates to the patients’ symptomatic cytopenias and their potential for progression to acute myeloid leukemia (AML). The patients’ generally elderly ages complicate management of the illness due to attendant comorbidities. Beyond standard supportive care with transfusions, virtually all treatments for MDS are currently experimental. This combination of characteristics has contributed to the difficulty in determining appropriate therapy for MDS patients. Fundamental to improving the care for these individuals is a more thorough clinical characterization and basic understanding of mechanisms causing the marrow hemopoietic dysfunction central to this disorder.

Given these features and the increasing incidence of MDS as our populations age, this book is quite germane in providing a comprehensive state-of-the-art update of the current status and recent advances in the field. It describes major treatises by an international group of MDS experts on the clinical classification, underlying pathogenetic mechanisms, and biologically targeted treatments of the disease. Each of the book’s 10 chapters provides critical insights into specific topics, demonstrating interconnections between subjects.

Chapter 1 reviews the current clinical and prognostic categorizations of MDS, describing the complexity of establishing disease diagnosis and the critical clinical and biological features used to categorize MDS prognostically so that effective management strategies may be undertaken. Chapter 2 provides more extensive descriptions and photomicrographs of the major...
criteria for the morphologic classifications of MDS, including those for both adult and pediatric patients.

In order to understand basic pathogenetic mechanisms underlying MDS, an indepth analysis of the multifactorial nature of the biological derangements causing marrow dysfunction in this disorder is provided in Chapter 3, including careful assessment of marrow stromal, immunologic, as well as stem cell abnormalities and dysregulation. Particular focus in this discourse depicts the changing patterns of the aberrant biology associated with evolving stages of MDS. This evaluation examines the molecular lesions and their influences which generate the initially slow but insidious course of the disease, with a subsequent frequent triggering to more active disease progression. The role of the senescence process in enhancing the vulnerability of aging itself for susceptibility to MDS is also discussed in detail.

Chapters 4 and 5 are critical extensions of the analysis of MDS pathobiology, evaluating recently determined major cytogenetic and molecular discoveries involved in the syndrome. These treatises review current insights into disease biology using novel investigative techniques, including microarray analysis of differential gene expression profiles.

A growing plethora of therapeutic options for MDS is becoming available, particularly using biologically specific targeted drugs for treating the disease. Clinical subsets of MDS patients have been defined and discussed in Chapter 6 wherein immunologic mechanisms and immune-modulating therapy may be effective. Chapter 7 comprehensively updates results of experimental clinical trials using the many and various new agents targeting specific pathogenetic features in MDS and the strategies being used for managing differing subtypes of MDS. Treatment with hematopoietic cytokines for management of the patients’ symptomatic cytopenias is reviewed in Chapter 8. Due to recently improved appreciation of the negative clinical consequences of iron overload for multiply transfused MDS patients and the current availability of novel oral iron chelators, interest has been rekindled for use of iron chelation therapy. The current management of iron overload, as well as the biologic derangements caused by tissue siderosis, are also discussed in this chapter.

The only potentially curative therapy for MDS is hematopoietic stem cell transplantation (HSCT). However, age limitations for this high-intensity form of treatment and its relative toxicity require careful consideration of eligibility criteria prior to application of this procedure. Results of HSCT
investigations using risk-based categorization of MDS patients and the newer preparative regimens (including reduced-intensity conditioning) are discussed in Chapter 9.

The complexity of the disease's clinical course and the multiple options for management approaches engender an element of uncertainty in the minds of many, patients and clinicians alike. These disconcerting issues have a particularly prominent impact on each MDS patient's quality of life. Such effects on the various domains comprising this component of the patients' lives (functional, emotional, physical, spiritual, and social) are reviewed in Chapter 10.

An important property of this book is the interconnectedness between chapters, engendering cross-fertilization for improved understanding of this disease. Numerous unique aspects of MDS have been incorporated into each chapter and the co-authors provide proposals for major future directions for the field. These comprehensive features should permit valuable insights for the reader into this potentially life-threatening illness and its effective management.